Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled Study on the Effect of Spironolactone, in Patients With Persistent Proteinuria on Long-Term Angiotensin Converting Enzyme Inhibitor Therapy, With or With Out an Angiotensin II Receptor Blocker

NCT00106561 is registered in ClinicalTrials.gov with Melbourne Health as lead sponsor.

NCT NCT00106561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00106561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled Study on the Effect of Spironolactone, in Patients With Persistent Proteinuria on Long-Term Angiotensin Converting Enzyme Inhibitor Therapy, With or With Out an Angiotensin II Receptor Blocker
Lead sponsor
Melbourne Health
Phase
Phase 2/3
Overall status
Completed
Start date
January 31, 2002
Completion date
September 30, 2004
Enrollment
60
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic nephropathy, glomerulonephritis, kidney disease, proteinuria